EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B

Steven W Pipe, Frank W G Leebeek, Michael Recht iD, Nigel S Key, Giancarlo Castaman, Wolfgang Miesbach iD, Susan Lattimore, Kathelijne Peerlinck, Paul Van der Valk, Michiel Coppens iD, Peter Kampmann, Karina Meijer und 26 weitere

New England Journal of Medicine · 23.02.2023 · 388 (8) · 706-718

DOI: 10.1056/nejmoa2211644 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 23.02.2023. Verfasst von Steven W Pipe und 37 weiteren Autor:innen. Beteiligte Einrichtung: From the Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor (S.W.P.); the Department of Hematology, Erasmus University Medica…. Hauptthemen laut MEDLINE: Genetic Therapy, Factor IX, Hemophilia B. Die Arbeit wurde bisher 380-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: uniQure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyFactor IXHemophilia BHemorrhageGenetic VectorsHumansDependovirusMale

Substanzen

Factor IXfactor IX-Padua

Autor:innen und Institutionen

  • From the Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor (S.W.P.); the Department of Hematology, Erasmus University Medical Center, University Medical Center Rotterdam, Rotterdam (F.W.G.L.), V…

ORCID-Profile: Michael Recht, Wolfgang Miesbach, Michiel Coppens, K John Pasi

Förderung

  • uniQure

Zitieren

APA

Pipe, S. W., Leebeek, F. W. G., Recht, M., Key, N. S., Castaman, G., Miesbach, W., Lattimore, S., Peerlinck, K., Van der Valk, P., Coppens, M., Kampmann, P., Meijer, K., O'Connell, N., Pasi, K. J., Hart, D. P., Kazmi, R., Astermark, J., Hermans, C. R. J. R., Klamroth, R., …, & Monahan, P. E. (2023). Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. New England Journal of Medicine, 388(8), 706-718. https://doi.org/10.1056/nejmoa2211644

Vancouver

Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, et al. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. New England Journal of Medicine. 2023;388(8):706-718. doi:10.1056/nejmoa2211644

BibTeX
@article{Pipe2023,
  author = {Pipe, Steven W and Leebeek, Frank W G and Recht, Michael and Key, Nigel S and Castaman, Giancarlo and Miesbach, Wolfgang and Lattimore, Susan and Peerlinck, Kathelijne and Van der Valk, Paul and Coppens, Michiel and Kampmann, Peter and Meijer, Karina and O'Connell, Niamh and Pasi, K John and Hart, Daniel P and Kazmi, Rashid and Astermark, Jan and Hermans, Cedric R J R and Klamroth, Robert and Lemons, Richard and Visweshwar, Nathan and von Drygalski, Annette and Young, Guy and Crary, Shelley E and Escobar, Miguel and Gomez, Esteban and Kruse-Jarres, Rebecca and Quon, Doris V and Symington, Emily and Wang, Michael and Wheeler, Allison P and Gut, Robert and Liu, Ying P and Dolmetsch, Ricardo E and Cooper, David L and Li, Yanyan and Goldstein, Brahm and Monahan, Paul E},
  title = {Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {8},
  pages = {706--718},
  doi = {10.1056/nejmoa2211644}
}
Kostenlos starten →